Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses
Yu‐Pei Chen(Sun Yat-sen University), Jun Ma(Shanghai Jiao Tong University), Yaqin Wang(Sun Yat-sen University), Jing Zeng(Nextomics Biosciences (China)), Guan‐Qun Zhou(Sun Yat-sen University), Jiayi Shen(Sun Yat-sen University), Yuan Zhang(Sun Yat-sen University), Qing‐Mei He(Sun Yat-sen University), Ying Sun(Qilu Hospital of Shandong University), Ling‐Long Tang(Sun Yat-sen University), Cheng Xu(Pennsylvania State University), Yan‐Ping Mao(Sun Yat-sen University), Xu Liu(Sun Yat-sen University), Lei Chen(Cincinnati Children's Hospital Medical Center), Na Liu(Sun Yat-sen University), Xiaomin Li(Committee on Publication Ethics), Rui Guo(Sun Yat-sen University), Jia‐Wei Lv(Zhejiang Chinese Medical University), Xiaojing Yang(Sun Yat-sen University), Wen‐Fei Li(Sun Yat-sen University), Jing‐Ping Yun(Sun Yat-sen University), Ying‐Qin Li(Sun Yat-sen University), Junyan Li(Sun Yat-sen University), Xiaojing Du(Sun Yat-sen University)
Cited by 99
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Majorbio Cloud: A one‐stop, comprehensive bioinformatic platform for multiomics analyses
|iMeta|2022|857